Hepatology

Late-breaking phase 3 data presented at EASL show elafibranor’s impact on managing PBC progression and improving itch-related quality of life in patients with pruritus.

Alkhouri explains the unmet need in MASH leading up to resmetirom’s historic FDA approval and the impact its availability has had for both patients and clinicians.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.

Aby describes findings from a pair of studies presented at DDW exploring the prevalence and impact of financial burden in liver transplant candidates.

Alkhouri explains survodutide’s mechanism of action as a glucagon/GLP-1 receptor dual agonist and reviews key findings about its use in MASH from the interim analysis.

End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the role of advocacy and patient voice in HBV management.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the most pressing unmet needs in HBV for 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on updates in the therapeutic pipeline.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the need to improve HBV screening and vaccination.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on how advancing understanding of HBV DNA integration is influencing care in 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on advances in the pathophysiology of hepatitis b virus for 2024.

Microbiota differences between individuals with and without MAFLD were associated with dietary intake and clinical outcomes.

Zhang explains disparities in HCC care and the negative impact on long-term outcomes, also addressing potential considerations for vulnerable patient populations.

Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.

In this Q&A, Levy discusses the current treatment landscape for PBC and what clinical trial data suggest about seladelpar’s potential for these patients.

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.

Patients who missed their initial HCV treatment appointment had greater housing instability, transportation difficulty, and a history of medication non-adherence.

An analysis of FDA Adverse Event Reporting System data suggests baloxavir marboxil has lower hepatic toxicity than oseltamivir and may be a safer option for patients with liver diseases.

Results of the single-center study showed HCV treatment from PCPs decreased from 2015-2022 but must be improved to help reach elimination goals.

Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.

Study results highlight the role of HCV and alcohol use in the growing global disease burden posed by cirrhosis, which is projected to increase over the next 20 years.

The CRL for the sBLA cites a lack of sufficient data to support the full evaluation of the effectiveness and safety of a 4-dose regimen in this patient population.

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.